Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice, Measured Using Patient-Reported Outcomes
Latest Information Update: 05 Jan 2024
At a glance
- Drugs Ustekinumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms Sirius
- Sponsors Janssen Pharmaceutical KK
- 31 Jan 2023 Status changed from active, no longer recruiting to completed.
- 12 Oct 2022 Planned primary completion date changed from 15 Dec 2022 to 14 Dec 2022.
- 17 Aug 2022 Planned primary completion date changed from 14 Dec 2022 to 15 Dec 2022.